Novo Nordisk A/s

Indiana University

Fa Liu

Richard Dennis DiMarchi

Jesper F Lau

Henning Thoegersen

Steffen Reedtz-Runge

Brian Finan

David L Smiley

Henning Thøgersen

Patrick J Knerr

Nicholas Cox

Wouter Frederik Johan Hogendorf

John Philip Mayer

Nicholas Raymond Cox

Richard D Dimarchi

Richard Dimarchi

The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particular the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH).

GIP derivatives and uses thereof

The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particularly the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH). The peptides comprise a lysine residue at a position corresponding to position 24 of hGIP(1-31), and comprise a negatively charged modifying group attached to the epsilon amino group of the lysine residue.

Disclosed herein are insulin agonist peptides conjugated to incretins wherein the incretin-insulin conjugate has agonist activity at the insulin receptor and the corresponding incretin receptor, and stimulates weight loss in an individual administered the compound.

Incretin-insulin conjugates

Growing community of inventors

Sammamish, WA, United States of America

Fa Liu